Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rangering i aksjer #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Aksjekurs
$0.00244926
Markedsverdi
$51.67K
Endring (1 dag)
5.88%
Endring (1 år)
110.15%
Land
GB
Handel Nuformix plc (NFX)

Kategori

Driftsmargin for Nuformix plc (NFX)
Driftsmargin per March 2026 TTM: 0.00%
Ifølge Nuformix plc sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 0.00%. Ved slutten av 2024 hadde selskapet en driftsmargin på 0.00%.
Historikk for driftsmargin for Nuformix plc fra 2014 til 2026
Driftsmargin ved slutten av hvert år
År Driftsmargin Endre
2026 (TTM) 0.00% 0.00%
2025 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% -100.00%
2022 -2,540.54% 261.58%
2021 -702.62% 309.40%
2020 -171.62% -42.18%
2019 -296.81% -97.73%
2018 -13,076.71% 0.00%
2017 0.00% -100.00%
2016 -57.68% -137.35%
2014 154.45% 0.00%
Driftsmargin for lignende selskaper eller konkurrenter
Selskap Driftsmargin Forskjell i driftsmargin Land
41.30% -
DK
35.45% -
US
24.95% -
US
25.32% -
BE
25.72% -
AU
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.